CORT-108297

CORT-108297
Clinical data
Other namesCORT108297; ADS-108297; ADS108297
Routes of
administration
Oral
Drug classAntiglucocorticoid; Selective glucocorticoid receptor modulator
ATC code
  • None
Identifiers
  • (4aR)-4a-(ethoxymethyl)-1-(4-fluorophenyl)-6-[4-(trifluoromethyl)phenyl]sulfonyl-4,5,7,8-tetrahydropyrazolo[5,4-g]isoquinoline
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC26H25F4N3O3S
Molar mass535.56 g·mol−1
3D model (JSmol)
  • CCOC[C@]12CC3=C(C=C1CCN(C2)S(=O)(=O)C4=CC=C(C=C4)C(F)(F)F)N(N=C3)C5=CC=C(C=C5)F
  • InChI=1S/C26H25F4N3O3S/c1-2-36-17-25-14-18-15-31-33(22-7-5-21(27)6-8-22)24(18)13-20(25)11-12-32(16-25)37(34,35)23-9-3-19(4-10-23)26(28,29)30/h3-10,13,15H,2,11-12,14,16-17H2,1H3/t25-/m1/s1
  • Key:SLKURXRZHJOZOD-RUZDIDTESA-N

CORT-108297, also known as ADS-108297, is a nonsteroidal selective glucocorticoid receptor modulator (SEGRM) with mixed glucocorticoid and antiglucocorticoid actions which is under development for the treatment of Alzheimer's disease, cognition disorders, memory disorders, and post-traumatic stress disorder (PTSD). It was also being developed for treatment of other psychiatric disorders and weight gain, but development for these indications was discontinued. The drug is taken by mouth. As of November 2022, CORT-108297 is in phase 2 clinical trials for the aforementioned active indications.

See also